Andrew Dudum Sells 36,460 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 36,460 shares of the company’s stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $28.04, for a total value of $1,022,338.40. Following the completion of the sale, the chief executive officer now owns 92,103 shares in the company, valued at $2,582,568.12. This represents a 28.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Monday, March 17th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.98, for a total value of $4,353,755.46.
• On Tuesday, February 18th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29.
• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.22, for a total transaction of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.08, for a total transaction of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.

Hims & Hers Health Price Performance

Shares of HIMS opened at $27.24 on Friday. The firm has a 50 day simple moving average of $37.26 and a two-hundred day simple moving average of $30.69. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The company has a market cap of $6.05 billion, a P/E ratio of 61.91 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the subject of several recent research reports. Bank of America boosted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Piper Sandler upped their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $38.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Crewe Advisors LLC acquired a new position in Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. grew its stake in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at $38,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.